Last Updated on October 10, 2024 by The Health Master
Glenmark Pharmaceuticals today said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray for the treatment of seasonal allergic rhinitis.
The company’s fully-owned unit Glenmark Specialty SA (Switzerland) has received approval from the USFDA for its New Drug Application (NDA) for Ryaltris, a fixed-dose (metered), prescription, combination nasal spray, Glenmark Pharmaceuticals said in a statement.
The product is used for the treatment of symptoms of seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older, it added.
“The USFDA’s approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to bring innovative treatment options in our key therapeutic areas,” said Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals.
With this NDA approval, the company looks forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms, he added.
Ryaltris will be marketed and distributed in the United States by Hikma Specialty USA, Inc, as part of its exclusive licensing agreement with Glenmark Specialty SA.
Ryaltris has been approved and is marketed in Australia, the Czech Republic, Poland, Russia, South Africa, Ukraine, the UK and Uzbekistan.
Glenmark concluded the regulatory procedure in Europe, enabling approval in 17 countries across the EU and the UK.
The drug firm has entered into commercial agreements with several partners around the world, including Menarini for the commercialization of the drug in select EU markets and with Bausch Health in Canada.
USFDA gives tentative nod to Alembic for Dronedarone tablets
USFDA gives nod to Alembic Pharma for Vortioxetine tablets
USFDA gives nod to Alembic for generic drug to treat Parkinson’s disease
USFDA gives nod to Alembic Pharma for Doxycycline Hyclate tablets
USFDA gives tentative nod to Zydus Cadila for Pimavanserin capsules
USFDA gives tentative nod to Amphastar Pharma for Vasopressin injection
Narcotic Control Bureau seizes Drugs worth Rs 30 lakh
Big Pharma Companies buying land in Hyderabad
Govt warns against overuse, misuse of COVID medicines
BIS notifies new standard for these Medical Devices
Licensing procedure for Medical devices
Latest Notifications: Medical Devices
Classifications of Medical Devices under the provisions of MDR 2017
FAQs on Medical Devices Rules, 2017
FAQs – on Blood Pressure Monitoring DevicesAlso read
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
